Tom has been with Versant Ventures since 2002. Most recently, Tom served as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. Tom led the process that culminated in the sale of Okairos to GSK for $325M.
Prior to his role with Okairos, Tom co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with Biotie), and Amira (acquired by BMS for up to $475M).
Tom was also Principal at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. In addition, Tom was a research scientist at XenoPort before joining Versant.